NVO Q2 2026: Profit Slide and Flat Guidance Reinforce Caution, but Wait for Revenue Quality Evidence

What happened

Novo Nordisk's Q2 2026 earnings revealed a 16% reported operating profit decline, including DKK 6.3B of pipeline impairments, while adjusted profit rose 11% but full-year guidance remains flat to negative at CER. The Seeking Alpha article downgrades NVO to Sell, citing falling profits, weak revenue growth, manufacturing setbacks, and patent expiries, contrasting sharply with Eli Lilly's momentum. However, the DeepValue master report notes that the stock at $45.3 already reflects these stresses with 11.2x P/E and 8.9x EV/EBITDA, and the key debate is whether the Wegovy pill's rapid prescription growth (265k weekly) can convert into reimbursed revenue before the 2027 price reset. Operational frailties like 90% self-pay reliance for the pill and employer coverage fatigue are genuine threats, but the Medicare GLP-1 Bridge launched July 1, 2026, could gradually improve payer mix, making a premature Sell rating risky if revenue quality inflects. The investment case hinges on the next 3-6 months of evidence on channel mix and realized pricing, not just demand strength.

Implication

Investors should brace for continued volatility as Novo navigates a brutal pricing environment and operational hurdles. The 2026 guidance for flat to negative growth underscores that volume gains alone cannot offset rebate pressure and self-pay dependence. However, the stock’s cheap valuation and strong cash generation provide a floor, and the Medicare Bridge launch offers a catalyst for reimbursement conversion. If Wegovy pill scripts continue rising but obesity revenue fails to reaccelerate above mid-single digits by early 2027, a more bearish stance is warranted. Conversely, successful payer mix improvement could lift shares back toward the $49 base case. Hold until September’s Capital Markets Day reveals more on gross-to-net and 2027 pricing architecture.

Thesis delta

The Seeking Alpha downgrade echoes the bearish scenario but does not alter our WAIT rating, as the Q2 data were already incorporated. A shift to Sell requires proof that Medicare Bridge cannot reduce self-pay reliance or that CagriSema timing slips further. We maintain that the stock is not a buy until revenue quality shows durable improvement.